The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review

Documents similaires

• Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis
  par: Sara Berg, et autres
  Publié: (2025)
• Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
  par: Deep Dutta, et autres
  Publié: (2024)
• Evaluation and Management of Polycystic Ovarian Syndrome (PCOS) in Adolescents With Obesity: A Scoping Review of National and International Obesity and PCOS Management Guidelines
  par: Carey Yun Shan Lim, et autres
  Publié: (2025)
• Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
  par: Abraish Ali, et autres
  Publié: (2025)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  par: Yunwen Xu, et autres
  Publié: (2025)